If you have been reading about alpha-MSH analogue and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-14. Numbers and descriptions here follow the published literature rather than marketing material.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic cyclic heptapeptide | Alpha-MSH analogue containing a D-phenylalanine residue |
| Molecular formula | C50H69N15O9 | Average molecular mass approximately 1024.2 g/mol |
| Appearance | White to off-white lyophilised powder | Normally supplied as a freeze-dried solid in a sealed vial |
| Solubility | Freely soluble in water and polar solvents | Dissolves readily in aqueous buffers and in alcohol-water mixtures |
| Receptor targets | MC1R, MC3R, MC4R, MC5R | Acts as a non-selective melanocortin receptor agonist |
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Liquid is a state of matter with a definite volume but no fixed shape. When confined in a container and subject to a force such as gravity, liquids will adapt to the internal shape of the container in the direction of the force. Liquids are nearly incompressible, maintaining their volume even under pressure. The density of a liquid is usually close to that of a solid, and much higher than that of a gas. Liquids are a form of condensed matter alongside solids, and a form of fluid alongside gases. A liquid is composed of atoms or molecules held together by intermolecular bonds of intermediate strength. These forces allow the particles to move around one another while remaining closely packed. In contrast, solids have particles that are tightly bound by strong intermolecular forces, limiting their movement to small vibrations in fixed positions. Gases, on the other hand, consist of widely spaced, freely moving particles with only weak intermolecular forces. As temperature increases, the molecules in a liquid vibrate more intensely, causing the distances between them to increase. At the boiling point, the cohesive forces between the molecules are no longer sufficient to keep them together, and the liquid transitions into a gaseous state. Conversely, as temperature decreases, the distance between molecules shrinks. At the freezing point, the molecules typically arrange into a structured order in a process called crystallization, and the liquid transitions into a solid state.
==== X-ray passport ==== Since 2002, an x-ray pass is a document in which the examining physician or dentist must enter information about the x-ray examinations performed on the patient. The main aim was to avoid unnecessary repeat examinations. According to the new Radiation Protection Ordinance (StrlSchV), practices and clinics are no longer obliged to offer their patients X-ray passports and to enter examinations in them. The Radiation Protection Ordinance came into force on December 31, 2018, together with the Radiation Protection Act (StrlSchG) passed in 2017, replacing the previous Radiation Protection Ordinance and the X-ray Ordinance. The Federal Office for Radiation Protection (BfS) continues to advise patients to keep records of their own radiation diagnostic examinations. On its website, the BfS provides a downloadable document that can be used for personal documentation.
brevicaule complex. DNA analysis however shows that more than 99% of all current varieties of potatoes are direct descendants of a subspecies that once grew in the lowlands of south-central Chile. Most modern potatoes grown in North America arrived through European settlement and not independently from the South American sources. At least one wild potato species, Solanum fendleri, occurs in North America; it is used in breeding for resistance to a nematode species that attacks cultivated potatoes. A secondary center of genetic variability of the potato is Mexico, where important wild species used extensively in modern breeding are found, such as the hexaploid S. demissum, used as a source of resistance to the devastating late blight disease (Phytophthora infestans). Another relative native to this region, Solanum bulbocastanum, has been used to genetically engineer the potato to resist potato blight. Many such wild relatives are useful for breeding resistance to P. infestans. Little of the diversity found in Solanum ancestral and wild relatives is found outside the original South American range. This makes these South American species highly valuable in breeding. The importance of the potato to humanity is recognised in the United Nations International Day of Potato, to be celebrated on 30 May each year, starting in 2024.
Tim Hortons had a presence on a number of military bases, including Kandahar in Afghanistan, although this latter outlet was principally intended for Canadian Armed Forces and allied military personnel. Three more outlets were in military bases at Aberdeen Proving Ground, Maryland, Fort Knox, Kentucky, and Naval Station Norfolk, Virginia. The latest location is at Camp Adazi in Latvia.
Sources: en.wikipedia.org
=== 2000: Glaxo Wellcome and SmithKline Beecham merger === Glaxo Wellcome and SmithKline Beecham announced their intention to merge in January 2000. The merger was completed on 27 December that year, forming GlaxoSmithKline (GSK). The company's global headquarters were at GSK House, Brentford, London, officially opened in 2002, by then-Prime Minister Tony Blair. The building was erected at a cost of £300 million and as of 2002 was home to 3,000 administrative staff.
== History == The first compact computer controlled robotic arms appeared in the early 1980s, and have continuously been employed in laboratories since then. These robots can be programmed to perform many different tasks, including sample preparation and handling. Yet in the early 1980s, a group led by Masahide Sasaki, from Kochi Medical School, introduced the first fully automated laboratory employing several robotic arms working together with conveyor belts and automated analyzers. The success of Sasaki's pioneer efforts made other groups around the world to adopt the approach of Total Laboratory Automation (TLA). Despite the undeniable success of TLA, its multimillion-dollar cost prevented that most laboratories adopted it. Also, the lack of communication between different devices slowed down the development of automation solutions for different applications, while contributing to keeping costs high. Therefore, the industry attempted several times to develop standards that different vendors would follow in order to enable communication between their devices. However, the success of this approach has been only partial, as nowadays many laboratories still do not employ robots for many tasks due to their high costs. Recently, a different solution for the problem became available, enabling the use of inexpensive devices, including open-source hardware, to perform many different tasks in the laboratory. This solution is the use of scripting languages that can control mouse clicks and keyboard inputs, like AutoIt.
=== Leucomatous corneal opacity (leucoma simplex) === Leucomatous corneal opacity is a dense white opacity which results due to scarring of more than half of the stroma. A number of different presentations of leucomatous corneal opacity exist:
===== Type 2B ===== This is a "gain of function" defect. The ability of the qualitatively defective VWF to bind to glycoprotein Ib (GPIb) receptor on the platelet membrane is abnormally enhanced, leading to its spontaneous binding to platelets and subsequent rapid clearance of the bound platelets and of the large VWF multimers. Thrombocytopenia may occur. Large VWF multimers are reduced or absent from the circulation. The ristocetin cofactor activity is low when the patient's platelet-poor plasma is assayed against formalin-fixed, normal donor platelets. However, when the assay is performed with the patient's own platelets (platelet-rich plasma), a lower-than-normal amount of ristocetin causes aggregation to occur. This is due to the large VWF multimers remaining bound to the patient's platelets. Patients with this subtype are unable to use desmopressin as a treatment for bleeding, because it can lead to unwanted platelet aggregation and aggravation of thrombocytopenia.
== Limitations == Like other staining methods, Van Gieson’s stain has limitations. It may miss very thin collagen fibrils, immature collagen can be faint or invisible with this stain. This can lead to an underestimation of collagen content. The red coloration can also fade if slides are not properly fixed or stored. The usage of the picric acid–acid fuchsin mixture tends to remove or significantly weaken majority of hematoxylin, resulting in nuclei that are faint or nearly invisible under the microscope.To overcome this, an iron-mordanted hematoxylin, such as Weigert’s hematoxylin, is typically used. Iron hematoxylins are more resistant to acid decolorization and preserve nuclear detail even after exposure to Van Gieson's solution.
Sources: en.wikipedia.org
Loperamide, sold under the brand name Imodium, among others, is a medication of the opioid receptor agonist class used to decrease the frequency of diarrhea. It is often used for this purpose in irritable bowel syndrome, inflammatory bowel disease, short bowel syndrome, Crohn's disease, and ulcerative colitis. Loperamide is taken by mouth. Common side effects include abdominal pain, constipation, sleepiness, vomiting, and dry mouth. It may increase the risk of toxic megacolon. Loperamide's safety in pregnancy is unclear, but no evidence of harm has been found. It appears to be safe in breastfeeding. It is an opioid with no significant absorption from the gut and does not cross the blood–brain barrier when used at normal doses. It works by slowing the contractions of the intestines. Loperamide was first made in 1969 and used medically in 1976. It is on the World Health Organization's List of Essential Medicines. Loperamide is available as a generic medication. In 2023, it was the 276th most commonly prescribed medication in the United States, with more than 800,000 prescriptions.
RGFP966, or RGFP-966, is a histone deacetylase (HDAC) inhibitor which is used in scientific research. It is a highly selective HDAC3 inhibitor. The drug is the most commonly used selective HDAC3 inhibitor in research.
=== Mechanically interlocked molecular architectures === Mechanically interlocked molecular architectures consist of molecules that are linked only as a consequence of their topology. Some non-covalent interactions may exist between the different components (often those that were used in the construction of the system), but covalent bonds do not. Supramolecular chemistry, and template-directed synthesis in particular, is key to the efficient synthesis of the compounds. Examples of mechanically interlocked molecular architectures include catenanes, rotaxanes, molecular knots, molecular Borromean rings, 2D [c2]daisy chain polymer and ravels.
=== 20th–21st century === After receiving greater financial autonomy in 1907, it began a new phase of growth. In 1934, the MNHN opened the Paris Zoological Park, a new zoo to in the Bois de Vincennes, as the home for the larger animals of the Menagerie of the Jardin des Plantes. In 1937, it opens the Musée de l'Homme, a museum of anthropology located in Palais de Chaillot, across the Seine from the Eiffel Tower, in a building created for the 1937 Paris International Exposition. In recent decades, it has directed its research and education efforts at the effects on the environment of human exploitation. In French public administration, the museum is classed as a grand établissement of higher education. Some of the buildings, particularly the Grand Gallery of Evolution, completed in 1889, were in poor condition by the mid-20th century. It was closed entirely in 1965, then underwent major restoration between 1991 and 1994 to its present state. In August 2025, the MNHN returned the skull of the Malagasy King Toera of Menabe, who was killed by French colonial soldiers in 1897, to Madagascar along with the skulls of two of his companions after more than a century of keeping the skulls in its archives. On 16 September 2025, multiple gold artefacts valued at €600,000 were stolen following a heist at the MNHN. A suspect was charged on 21 October 2025 in connection with the heist.
Sources: en.wikipedia.org
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.
No approved regulatory indication exists in major markets. An approval exists for a different peptide, afamelanotide, which is used for a rare photosensitivity disorder called erythropoietic protoporphyria. Melanotan-2 itself remains a research compound with no cleared clinical role.
Melanocortin-1 receptors on melanocytes are the receptor most closely linked to pigment production. The peptide is not selective, however, and also activates melanocortin-3, melanocortin-4, and melanocortin-5 receptors. That lack of selectivity is the usual explanation offered for both its range of observed effects and its off-target effects.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.